Autolus Therapeutics plc Increase (Decrease) in Inventories
Autolus Therapeutics plc (AUTL) reported Increase (Decrease) in Inventories of $3.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-11
- Autolus Therapeutics plc increase (decrease) in inventories for the quarter ending 2026-06-30 was $1.19M, a 89.57% decline year-over-year.
- Autolus Therapeutics plc increase (decrease) in inventories for the quarter ending 2026-03-31 was $2.54M, a 74.84% decline year-over-year.
- Autolus Therapeutics plc increase (decrease) in inventories for the quarter ending 2025-12-31 was $10.11M, a 139.06% increase year-over-year.
- Autolus Therapeutics plc increase (decrease) in inventories for the quarter ending 2025-09-30 was $8.60M.
- Autolus Therapeutics plc increase (decrease) in inventories for fiscal 2025 was $40.25M, a 851.76% increase from fiscal 2024.
- Autolus Therapeutics plc increase (decrease) in inventories for fiscal 2024 was $4.23M.
- Autolus Therapeutics plc increase (decrease) in inventories for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.73M 10-Q · filed 2026-08-11 | $13.84M derived: sum of 3 quarters · filed 2026-08-11 | $22.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.54M 10-Q · filed 2026-05-14 | $12.65M derived: sum of 2 quarters · filed 2026-05-14 | $21.25M derived: sum of 3 quarters · filed 2026-05-14 | $32.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $10.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $18.71M derived: sum of 2 quarters · filed 2026-03-27 | $30.15M derived: sum of 3 quarters · filed 2026-08-11 | $40.25M 10-K · filed 2026-03-27 |
| 2025-09-30 | $8.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $20.04M derived: sum of 2 quarters · filed 2026-08-11 | $30.14M 10-Q · filed 2025-11-12 | $34.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $11.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $21.54M 10-Q · filed 2026-08-11 | $25.77M derived: sum of 3 quarters · filed 2026-08-11 | $25.77M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $10.10M 10-Q · filed 2026-05-14 | $14.33M derived: sum of 2 quarters · filed 2026-05-14 | $14.33M derived: sum of 3 quarters · filed 2026-05-14 | $14.33M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $4.23M derived: sum of 2 quarters · filed 2026-03-27 | $4.23M derived: sum of 3 quarters · filed 2026-03-27 | $4.23M 10-K · filed 2026-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |